2022

1. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

   The Lancet Infectious Diseases, Vol. 22, Núm. 3, pp. 329-340